More than a week ago, on April 13, TFI did a story about how American big media is aggressively promoting a drug called Remdesivir by biotech firm named Gilead Sciences as the “best shot” against Coronavirus. The story, titled- ‘Buy Gilead, not HCQ,’ American media is rattled by the success of Indian HCQ and the reason is business– is available on the link given below.
A few days ago, on April 19, TFI again did a story how the global media and research organizations sponsored by left-liberal establishment are carrying out faulty trials of HCQ in order to discredit the cheap anti-malarial drug, which would also increase the chances of giving shot at costly Remdesivir by Gilead. The story can be read from the link below.
Remdesivir was developed to cure Ebola virus but the drug failed and as the disease was wiped out very soon, the investment made by Gilead was wasted. But the company is trying to recover the cost by promoting it as “best shot” against Coronavirus so that it would not only recover the investment made in research, but also make huge profits.
But now it has come to light that Remdesivir has failed to cure Coronavirus, too. WHO, the corrupt and criminally incompetent organization, accidentally published a study about the trial of the drug in China on its website, and a medical news website named STAT captured a screenshot of this post before it was taken down from the WHO website.
As per the study accidentally published by WHO, in the Chinese trial the drug failed to improve patients’ or reduce the presence of viral load in bloodstream. The trial enrolled 237 patients with 158 receiving Remdesivir while the rest receiving Placebo.
The drug failed to improve the condition of any patient and death rate was also similar. In fact, death rate was higher at 13.9 percent for Remdesivir against 12.8 percent for the control group.
The company tried to defend the drug by saying that the posted study by WHO was not peer-reviewed and included inappropriate characterization of the study which was terminated early and hence cannot be used for meaningful conclusion.
“The study results are inconclusive, though trends in the data suggest a potential benefit for Remdesivir, particularly among patients treated early in disease,” the company said without providing details to back up that assertion.
However, all this finely crafted technical jargon was of no use, as the share prices of the company, which were growing at double digit in the last few days, fell by 9 percent after the study about the drug was accidentally published by WHO.
The big business media companies like Bloomberg and Forbes were aggressively promoting Remdesivir. The same firms which argued that there is no scientific evidence of Hydroxychloroquine (HCQ)’s effectiveness as preventive drug are now writing articles that how more Gilead’s drug is magically improving the conditions majority of Coronavirus disease patients.
Bloomberg, the ring leader of big financial media house, published a story titled “Two-Thirds of Severe Covid-19 Cases Improved on Gilead Drug” on April 11 to promote the anti-Covid-19 drug developed by Gilead Sciences. The link of the story is given below:
On April 10, the same Bloomberg published a story titled, “Malaria Drug Hype Lures Macron as Hope Gets Ahead of Science” mimicking the faith of French President in the drug that is primarily produced in India.
On this, Nassim Nicholas Taleb, the famous philosopher and economist who was among the first few intellectuals to point out towards the dangers of not taking tough steps towards containment of this pandemic, tweeted, “Chloroquine: Does Big Pharma owns the media? + Studies are said to be “not rigorous” when it comes to Chloroquine in spite of robust statistical signal + Studies w/less rigor and significance are promoted when it comes to drugs by Gilead Note: Chl was OTC, costs 1 Euro a pack,” with image of both Bloomberg stories in contrast.
Chloroquine: Does Big Pharma owns the media?
+ Studies are said to be "not rigorous" when it comes to Chloroquine in spite of robust statistical signal
+ Studies w/less rigor and significance are promoted when it comes to drugs by Gilead
Note: Chl was OTC, costs 1 Euro a pack. pic.twitter.com/UU2URRxWNV
— Nassim Nicholas Taleb (@nntaleb) April 11, 2020
So far, HCQ, an anti-malarial drug primarily produced in India, has proved to be the best preventive medicine against Coronavirus. Many medical bodies across the world approved HCQ as preventive drug.
The approval of HCQ as preventive drug is a great news for India and its pharmaceutical industry, as more than 70 percent of the global supply of the drug is met by Indian companies- primarily Ipca Labs and Zycus.
Presently India produces 20 crore tablets of HCQ per month to meet domestic and global demand, and production capacity could be ramped up if needed. As per a report by Business Today, the pharmaceutical companies shall increase the production capacity to 5-6 times in the coming months to make hundreds of crores of tablets per month. Of these, 10 crore tablets would be kept for Indian use while the rest would be exported to the United States and other neighboring countries.